Transparency in Decision Modelling: What, Why, Who and How?
Authors:
- Christopher James SampsonCSChristopher James Sampson
- Renée ArnoldRARenée Arnold
- Stirling BryanSBStirling Bryan
- Philip ClarkePCPhilip Clarke
- Sean EkinsSESean Ekins
- Anthony HatswellAHAnthony Hatswell
- Neil HawkinsNHNeil Hawkins
- Sue LanghamSLSue Langham
- Deborah MarshallDMDeborah Marshall
- Mohsen SadatsafaviMSMohsen Sadatsafavi
- Will SullivanWSWill Sullivan
- Edward C. F. WilsonEWEdward C. F. Wilson
- 26 June 2019
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 37 (11) , 1355-1369
Abstract
Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the ‘what’, ‘why’, ‘who’ and ‘how’. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.Keywords
This publication has 51 references indexed in Scilit:
- Decoupling the scholarly journalFrontiers in Computational Neuroscience, 2012
- Addressing the Challenge for Well Informed and Consistent Reimbursement DecisionsPharmacoEconomics, 2011
- Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plansRheumatology, 2011
- Assessing the Performance of a Computer-Based Policy Model of HIV and AIDSPLOS ONE, 2010
- Time for Cooperation in Health Economics among the Modelling CommunityPharmacoEconomics, 2010
- Use of evidence in economic decision models: practical issues and methodological challengesHealth Economics, 2007
- Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2007
- Building Bridges Between Academic Research and Policy FormulationPharmacoEconomics, 2006
- Being economical with the truth: how to make your idea appear cost effectiveEmergency Medicine Journal, 2002
- Publication Bias in Clinical Trials and Economic AnalysesPharmacoEconomics, 1997